DEA and HHS Extend Telemedicine Flexibilities for Remote Prescription Through 2026
MobiHealthNews
|
Contributed by: Kate Gamble
Summary
The U.S. Drug Enforcement Administration (DEA) and the Department of Health and Human Services (HHS) have enacted a Fourth Temporary Extension of COVID-19 telemedicine flexibilities, allowing healthcare providers to remotely prescribe Schedule II-V controlled substances following an initial in-person evaluation. This policy, which continues until December 31, 2026, maintains accessibility to critical medications while mandating compliance with federal and state regulations. The decision enables both ongoing remote care and the responsible management of high-abuse potential medications, highlighting a significant evolution in how healthcare technology supports medication management amidst shifting regulatory landscapes. This development underscores the importance of telehealth in addressing patient needs, especially regarding substance use disorders.
